Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Genetics of Developmental Disorders
-
1. Imprinting disorders associated with molecular changes on chromosome 11p15
- Prof. Rosanna Weksberg
-
2. Chromatin genes and disease
- Prof. Richard Gibbons
-
3. Heterochromatin, epigenetics and gene expression
- Prof. Joel C. Eissenberg
- Cardiopulmonary Disease
-
4. Transcription factors and complex disease development
- Dr. Ines Pineda-Torra
-
5. Molecular genetics of pulmonary arterial hypertension
- Prof. Richard C. Trembath
- Neuromuscular System Diseases
-
6. Gene therapy for the muscular dystrophies
- Prof. Jeff Chamberlain
-
7. RAS pathway and disease: neurofibromatosis and beyond
- Prof. Eric Legius
-
8. Congenital syndromes of pain and painlessness
- Prof. Geoff Woods
- Prof. James Cox
- Endocrinology and Metabolism
-
9. Changing lives: stratified medicine in monogenic diabetes
- Prof. Andrew Hattersley
-
10. Genetics of monogenic obesity 1
- Prof. Dr. Johannes Hebebrand
- Prof. Dr. Anke Hinney
-
11. Genetics of monogenic obesity 2
- Prof. Dr. Johannes Hebebrand
- Prof. Dr. Anke Hinney
- Cancer Genetics
-
13. Inherited predisposition to breast cancer
- Prof. Diana Eccles
-
14. Genetics of breast and ovarian cancer
- Prof. Jeffrey Weitzel
-
16. NF2-related Schwannomatosis and Gorlin Syndrome
- Prof. D. Gareth R. Evans
-
17. The genetic basis of kidney cancer
- Dr. W. Marston Linehan
- Oligogenic and Complex Diseases
-
18. Ciliopathies and oligogenic phenomena
- Prof. Nicholas Katsanis
- Therapy
-
19. Mismatch repair deficient cancers & Lynch syndrome
- Prof. Sir John Burn
- Archived Lectures *These may not cover the latest advances in the field
-
20. Mismatch repair deficient cancers: diagnosis, treatment and prevention
- Prof. Sir John Burn
-
21. NF2 & Gorlins
- Prof. D. Gareth R. Evans
Printable Handouts
Navigable Slide Index
- Introduction
- Heterochromatin
- Types of heterochromatin
- Heterochromatin varies in different cell types
- Barr body heterochromatin in a female nucleus
- white gene expression results in a red eye
- Chromosome inversion displaces the white gene
- Euchromatic region silenced by heterochromatin
- HP1 affects heterochromatin silencing
- HP1 in heterochromatin and euchromatic sites
- Su(var)3-9 mutations suppress silencing
- HP1 invades PEV-inactivated euchromatic regions
- Heterochromatin silencing at the molecular level
- Heterochromatization - effects on methylation
- DNA accessibility to methylase in vivo
- Gene silencing by heterochromatin occlusion
- Nucleosomes are ordered in heterochromatin
- HP1 loss causes silencing of the light gene
- HP1-dependent heterochromatin gene expression
- SU(VAR)3-9-HP1-nucleosome interaction
- HP1 & H3K9me3 methyl mark do not co-localize
- Histone methylation is reversible
- Transcription results in chromatin demethylation
- Phosphorylation at H3S10 evicts HP2
- Epigenetics
- Active vs. epigenetically silenced chromatin
- Epigenetic stability through mitosis
- SU(VAR)3-9 and epigenetic memory
- Transgene reporter for heterochromatin silencing
- Promoter strength and heterochromatin silencing
- Heterochromatin silencing upon differentiation
- Silencing in differentiating & undifferentiated cells
- Loss of HP1 results in telomere fusions
- Telomere elongation in heterozygous HP1 mutants
- Het-A telomeric retro element transcription & HP2
- RNAi and the targeting of heterochromatin
- HP1 binds telomeres regardless of sequence
- Meiotically heritable RNAi-mediated silencing (1)
- Meiotically heritable RNAi-mediated silencing (2)
- Acknowledgments
Topics Covered
- Heterochromatin as a cytological phenomenon
- Heterochromatin and gene silencing
- Heterochromatin and DNA accessibility
- Histone modification and control of heterochromatin assembly
- Stability of epigenetic silencing by heterochromatin during development
- Heterochromatin and telomere stability
Links
Series:
Categories:
Talk Citation
Eissenberg, J.C. (2014, February 4). Heterochromatin, epigenetics and gene expression [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 14, 2024, from https://doi.org/10.69645/GMPK7246.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Joel C. Eissenberg has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
The title of this talk
is Heterochromatin,
Epigenetics and Gene Expression.
I'm Joel Eissenberg.
I'm a professor in the
Department of Biochemistry
and Molecular Biology at Saint
Louis University School of Medicine.
My goal in this talk is to
survey our understanding
of heterochromatin
and its connection
to the idea of epigenetic
control of gene expression.
Terms like heterochromatin
and epigenetics
are frequently used to
disguise, rather than explicate,
our understanding of
how cells organize
and use genetic information.
In this presentation,
I'll define these terms
and discuss epigenetics in
the context of heterochromatin
and the evidence that it can
influence gene expression.
0:47
The term heterochromatin
was coined by Emil Heitz
to refer to the material in the
eukaryotic nucleus that fails
to decondense after
telophase in the cell cycle.
On the left in this slide is an
image showing the chromosomes
of a cell at or near telophase
stained with a fluorescent dye
that labels DNA.
The bright fluorescent staining, is
coextensive with the chromosomes.
In contrast, the interphase nucleus
on the right is filled with DNA,
but only certain regions stain
brightly, the heterochromatin.
The condensed state
of heterochromatin
concentrates the DNA, making these
regions stand out on the background
of the rest of the DNA
fluorescents in the nucleus.
This property distinguishes
it from the remaining
so-called euchromatin, or
true chromatin, that undergoes
cyclic condensation
and decondensation.
In contrast, heterochromatin
exhibits heterocyclic behavior,
hence the term heterochromatin.
Thus, the term
heterochromatin was originally
coined to describe a
cytological phenomenon, not
a genetic or biochemical phenomenon.
Heitz ultimately showed that most
or all eukaryotic chromosomes
are differentiated
along their lengths
by zones of euchromatin, which he
recognized as relatively gene rich,
and heterochromatin, which he
recognized as relatively gene poor.
More recently, the
term heterochromatin
has been used more promiscuously
to describe any form of chromatin
associated with
transcriptional silencing
and/or chromatin enriched for
certain biochemical markers,
such as cytosine methylation, or
certain histone modifications.
In this presentation, I'll
stick to examples that
are consistent with the
original definition of the word.